Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Poly(amino acid) targeting moieties

Inactive Publication Date: 2009-03-19
THE BRIGHAM & WOMENS HOSPITAL INC +1
View PDF28 Cites 239 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0033]In another embodiment of the controlled-release system of the invention, the polymeric matrix is surrounded by a lipid monolayer shell. In one embodiment, the lipid

Problems solved by technology

Targeted delivery for diagnosis and therapeutic applications has until recently largely been limited to receptor ligands such as antibodies, modified-antibodies and nucleic acids.
The large size of antibody molecules can be advantageous for bimodal binding mechanisms but it may also lead to poor solid penetration and slow elimination from the blood circulation.
Unfortunately, slow elimination kinetics can cause myelotoxicity.
In addition, its in vivo application has been proven more challenging because of cost and potential immunogenicity after repeat injections of such formulations.
To avoid these problems, Fab's and scFv have successfully been made but are still too large.
However, the effects of the increased permeability are offset by the more rapid excretion of the antibody fragments which decreases the ability of the antibody to cross membranes resulting in lower absolute tumor levels as well as lower blood and tissue levels.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Poly(amino acid) targeting moieties
  • Poly(amino acid) targeting moieties
  • Poly(amino acid) targeting moieties

Examples

Experimental program
Comparison scheme
Effect test

example 1

Amphiphilic Nanoparticle with Aptamer

[0238]In one embodiment, the A10 RNA aptamer which binds to the Prostate Specific Membrane Antigen (PSMA) on the surface of prostate cancer cells is conjugated to DSPE (1,2-Distearoyl-sn-glycero-3-phosphoethanolamine)-PEG-COOH using EDC / NHS chemistry with a conjugate concentration of 0.7 mg / mL. 0.21 mg of this DSPE-PEG-aptamer bioconjugate is mixed with 0.07 mg lecithin in 2 mL aqueous solution containing 4% ethanol. 1 mg poly(D,L-lactic-co-glycolic acid) (PLGA, Mw=100 kD) is dissolved in 1 mL tetrahydrofuran (THF) solvent, to which 5% docetaxel of the mass of PLGA is added. This PLGA solution is then mixed with the aqueous solution of lecithin / DSPE-PEG-Aptamer. These mixtures are vortexed for 3 minutes, followed by stirring for 2 hours. In order to remove all organic solvents, these mixtures are then dialyzed for another 4 hours against PBS buffer. This procedure would yield nanoparticles targeting to prostate cancer cells expressing PSMA antige...

example 2

Amphiphilic Nanoparticle with CREKA

[0242]The peptide CREKA is conjugated to DSPE-PEG-Maleimide before formulating nanoparticles using the protocol of Example 1. This peptide will target the delivery and uptake of the nanoparticles to extracellular basement membranes which are exposed under the leaky endothelial layer covering atherosclerotic plaques.

example 3

Amphiphilic Nanoparticle with AXYLZZLN

[0243]The peptide AXYLZZLN, or conservative variants or peptidomimetics thereof, wherein X and Z are variable amino acids, can be conjugated to DSPE-PEG-Maleimide before formulating nanoparticles using the protocol of Example 1. This peptide will target the delivery and uptake of the nanoparticles to extracellular basement membranes which are exposed under the leaky endothelial layer covering atherosclerotic plaques.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Ratioaaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to View More

Abstract

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 60 / 910,097, Attorney Docket No. BBZ-011-1, filed Apr. 4, 2007, titled “Amphiphilic compound assisted polymeric particles for targeted delivery;” U.S. Provisional Application No. 60 / 985,104, Attorney Docket No. BBZ-011-2, filed Nov. 2, 2007, titled “Lipid-Stabilized Polymeric Nanoparticles for Targeted Drug Delivery;” U.S. Provisional Application No. 60 / 938,590, Attorney Docket No. BBZ-012-1, filed May 17, 2007, titled “Poly(Amino Acid)-Targeted Drug Delivery;” U.S. Provisional Application No. 60 / 986,202, Attorney Docket No. BBZ-012-2, filed Nov. 7, 2007, titled “Poly(Amino Acid)-Targeted Drug Delivery;” and U.S. Provisional Application No. 60 / 990,250, Attorney Docket No. BBZ-012-3, filed Nov. 26, 2007, titled “Poly(Amino Acid)-Targeted Drug Delivery;” all of which are incorporated herein by reference in their entirety. Additionally, the contents of any patents, patent applications, and ref...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/14A61K47/42A61K31/135A61K31/337A61K38/16A61K31/4353A61K31/56A61K9/00C07K5/10A61P9/00
CPCA61K9/5123A61K9/5153A61K9/5192B82Y5/00A61K47/48907A61K47/48915A61K47/48238A61K47/62A61K47/6935A61K47/6937A61P9/00A61P9/08A61P9/10A61P9/14A61P35/00A61P37/04
Inventor ALEXIS, FRANKZHANG, LIANGFANGRADOVIC-MORENO, ALEKSANDAR F.GU, FRANK X.BASTO, PAMELALEVY-NISSENBAUM, ETGARCHAN, JULIANALANGER, ROBERT S.FAROKHZAD, OMID C.
Owner THE BRIGHAM & WOMENS HOSPITAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com